Glomerular disease related to anti-VEGF therapy (Q81441190)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18547991%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Glomerular disease related to anti-VEGF therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18547991%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18547991%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Maria C Erazo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18547991%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Vivette D D'Agati

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18547991%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

English

0 references

publication date

11 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18547991%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18547991%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18547991%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18547991%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

1487-1491

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18547991%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/ki.2008.256

8 January 2020

exact match

0 references

cites work

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

Managing patients treated with bevacizumab combination therapy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

Thrombotic microangiopathy and anti-VEGF agents

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

Nephrotic syndrome after bevacizumab: case report and literature review

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

The role of vascular endothelial growth factor (VEGF) in renal pathophysiology

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

Role of the VEGF--a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

Circulating angiogenic factors and the risk of preeclampsia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

Collapsing glomerulopathy in renal allografts: a morphological pattern with diverse clinicopathologic associations

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021

Sickle cell disease, nephrotic syndrome, and renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.256

7 January 2021